$OSUR
OraSure Technologies Inc

2017 Q4 Form 10-Q Financial Statement

#000119312517338742 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q4
Revenue $52.03M $42.31M $35.50M
YoY Change 46.56% 31.2% 9.63%
Cost Of Revenue $23.50M $17.67M $11.55M
YoY Change 103.46% 84.52% 10.53%
Gross Profit $28.53M $24.64M $23.95M
YoY Change 19.12% 8.68% 9.21%
Gross Profit Margin 54.84% 58.24% 67.47%
Selling, General & Admin $14.54M $14.10M $15.67M
YoY Change -7.21% 5.71% 3.43%
% of Gross Profit 50.96% 57.2% 65.43%
Research & Development $3.830M $3.228M $1.210M
YoY Change 216.53% 1.0% -55.02%
% of Gross Profit 13.42% 13.1% 5.05%
Depreciation & Amortization $1.490M $1.698M $1.490M
YoY Change 0.0% 20.08% 3.47%
% of Gross Profit 5.22% 6.89% 6.22%
Operating Expenses $18.37M $17.33M $16.88M
YoY Change 8.83% 4.8% -5.38%
Operating Profit $10.16M $7.319M $7.073M
YoY Change 43.66% 19.12% 72.85%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $118.0K $113.0K $92.00K
YoY Change 28.26% -77.31% -75.73%
Pretax Income $10.28M $7.432M $7.165M
YoY Change 43.46% 11.89% 60.25%
Income Tax $2.963M $1.669M -$31.00K
% Of Pretax Income 28.83% 22.46% -0.43%
Net Earnings $7.316M $5.763M $7.196M
YoY Change 1.67% -7.67% 55.89%
Net Earnings / Revenue 14.06% 13.62% 20.27%
Basic Earnings Per Share $0.12 $0.10 $0.13
Diluted Earnings Per Share $0.12 $0.09 $0.13
COMMON SHARES
Basic Shares Outstanding 60.65M shares 60.09M shares 55.73M shares
Diluted Shares Outstanding 62.17M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $154.1M $160.1M $119.1M
YoY Change 29.39% 34.2% 17.57%
Cash & Equivalents $71.03M $76.77M $108.0M
Short-Term Investments $83.00M $83.40M $11.20M
Other Short-Term Assets $2.486M $1.206M $2.143M
YoY Change 16.01% 82.73% 58.15%
Inventory $19.34M $16.86M $11.80M
Prepaid Expenses $1.658M $1.189M $1.722M
Receivables $42.52M $28.10M $19.83M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $221.9M $209.3M $156.4M
YoY Change 41.85% 38.89% 14.43%
LONG-TERM ASSETS
Property, Plant & Equipment $21.37M $21.50M $20.03M
YoY Change 6.68% 7.11% -0.25%
Goodwill $20.08M $20.26M $18.79M
YoY Change 6.86% 5.27% 2.98%
Intangibles $8.223M $8.972M $10.34M
YoY Change -20.45% -19.93% -17.9%
Long-Term Investments $20.70M $18.30M
YoY Change
Other Assets $3.928M $3.909M $2.331M
YoY Change 68.51% 68.35% 38.5%
Total Long-Term Assets $74.30M $72.92M $51.49M
YoY Change 44.28% 38.01% -2.12%
TOTAL ASSETS
Total Short-Term Assets $221.9M $209.3M $156.4M
Total Long-Term Assets $74.30M $72.92M $51.49M
Total Assets $296.2M $282.3M $207.9M
YoY Change 42.45% 38.66% 9.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.23M $9.624M $4.633M
YoY Change 120.76% 117.64% -8.92%
Accrued Expenses $20.70M $15.81M $11.31M
YoY Change 82.91% 64.41% 8.66%
Deferred Revenue $1.314M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.24M $26.62M $17.34M
YoY Change 85.96% 21.28% -31.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.932M $3.928M $2.304M
YoY Change 70.66% 71.6% 30.32%
Total Long-Term Liabilities $3.932M $3.928M $2.304M
YoY Change 70.66% 71.6% 30.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.24M $26.62M $17.34M
Total Long-Term Liabilities $3.932M $3.928M $2.304M
Total Liabilities $36.17M $30.55M $19.64M
YoY Change 84.17% 26.04% -27.27%
SHAREHOLDERS EQUITY
Retained Earnings -$119.5M -$126.8M -$150.5M
YoY Change -20.57% -19.55% -11.59%
Common Stock $387.9M $386.0M $350.5M
YoY Change 10.67% 11.15% 1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $258.1M $249.5M $185.9M
YoY Change
Total Liabilities & Shareholders Equity $296.2M $282.3M $207.9M
YoY Change 42.45% 38.66% 9.83%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income $7.316M $5.763M $7.196M
YoY Change 1.67% -7.67% 55.89%
Depreciation, Depletion And Amortization $1.490M $1.698M $1.490M
YoY Change 0.0% 20.08% 3.47%
Cash From Operating Activities -$2.200M $8.660M -$580.0K
YoY Change 279.31% 2.61% -187.88%
INVESTING ACTIVITIES
Capital Expenditures -$880.0K $1.895M -$840.0K
YoY Change 4.76% 142.02% -54.59%
Acquisitions
YoY Change
Other Investing Activities -$2.460M -$45.91M -$3.710M
YoY Change -33.69%
Cash From Investing Activities -$3.320M -$47.81M -$4.560M
YoY Change -27.19% 6029.49% 145.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 270.0K 10.36M 1.620M
YoY Change -83.33% 3137.5% -132.86%
NET CHANGE
Cash From Operating Activities -2.200M 8.660M -580.0K
Cash From Investing Activities -3.320M -47.81M -4.560M
Cash From Financing Activities 270.0K 10.36M 1.620M
Net Change In Cash -5.250M -28.79M -3.520M
YoY Change 49.15% -460.78% -42.58%
FREE CASH FLOW
Cash From Operating Activities -$2.200M $8.660M -$580.0K
Capital Expenditures -$880.0K $1.895M -$840.0K
Free Cash Flow -$1.320M $6.765M $260.0K
YoY Change -607.69% -11.65% -89.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2008Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
25000000
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60648324 shares
CY2016Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113536000
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
494000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15813000
CY2017Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
659000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
209335000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28099000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
688000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38689000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
385978000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9624000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
9338000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9638000
CY2017Q3 us-gaap Assets
Assets
282259000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
101662000
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
101962000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76770000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78610000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60631000 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60631000 shares
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q3 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
3670000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1186000
CY2017Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2194000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8684000
CY2017Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18129000
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8972000
CY2017Q3 us-gaap Goodwill
Goodwill
20257000
CY2017Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8972000
CY2017Q3 us-gaap Inventory Net
InventoryNet
16859000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6861000
CY2017Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
8252000
CY2017Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1746000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
282259000
CY2017Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26623000
CY2017Q3 us-gaap Line Of Credit
LineOfCredit
0
CY2017Q3 us-gaap Long Term Investments
LongTermInvestments
18290000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2479000
CY2017Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1206000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3909000
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3928000
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1189000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21496000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1840000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126826000
CY2017Q3 us-gaap Short Term Investments
ShortTermInvestments
83372000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
249514000
CY2017Q3 osur Taxes Payable Receivable Current And Noncurrent
TaxesPayableReceivableCurrentAndNoncurrent
3303000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94094000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
484000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11314000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
715000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
156441000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19827000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
982000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36067000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
350528000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4633000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14220000
CY2016Q4 us-gaap Assets
Assets
207935000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
11160000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
11160000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107959000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109790000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56001000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56001000 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
1980000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1388000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2446000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7685000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15197000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10337000
CY2016Q4 us-gaap Goodwill
Goodwill
18793000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10337000
CY2016Q4 us-gaap Inventory Net
InventoryNet
11799000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5366000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5399000
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1034000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207935000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17335000
CY2016Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1971000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2143000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2331000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2304000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1722000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20033000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1831000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150458000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
11160000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
185850000
CY2016Q4 osur Taxes Payable Receivable Current And Noncurrent
TaxesPayableReceivableCurrentAndNoncurrent
-39000
CY2017Q2 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
2600000
dei Amendment Flag
AmendmentFlag
false
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1984000
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
300000
us-gaap Contracts Revenue
ContractsRevenue
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31180000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28214000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
44605000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-425000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4589000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1317000
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.40
dei Entity Registrant Name
EntityRegistrantName
ORASURE TECHNOLOGIES INC
dei Entity Central Index Key
EntityCentralIndexKey
0001116463
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
619000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1256000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
246000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21777000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
30753000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7706000
us-gaap Gross Profit
GrossProfit
70431000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
12500000
us-gaap Income Taxes Paid
IncomeTaxesPaid
4317000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-212000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4193000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4886000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2058000 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7121000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4593000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1616000
us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.00375 pure
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
30361000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Line Of Credit Facility Collateral
LineOfCreditFacilityCollateral
Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-09-30
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-300000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-93026000
us-gaap Operating Expenses
OperatingExpenses
40354000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
30168000
us-gaap Net Income Loss
NetIncomeLoss
23632000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
437000
us-gaap Operating Income Loss
OperatingIncomeLoss
30077000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4882000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
3265000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
676000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
132177000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1234000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3462000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
42613000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31402000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9536000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
724000 shares
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Deferred Revenue</u>.</i> We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September&#xA0;30, 2017 and December&#xA0;31, 2016 was comprised of customer prepayments of $1,186 and $1,388, respectively.</p> </div>
us-gaap Revenue Recognition Sales Returns
RevenueRecognitionSalesReturns
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <u><i>Customer Sales Returns and Allowances</i></u>. We do not grant return rights to our customers for any product, except for our OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of September&#xA0;30, 2017 and December&#xA0;31, 2016, the reserve for sales returns and allowances was $186 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product&#x2019;s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.</p> </div>
us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
186000
us-gaap Revenues
Revenues
115036000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
111771000
us-gaap Share Based Compensation
ShareBasedCompensation
5213000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
21541000
dei Trading Symbol
TradingSymbol
OSUR
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60569000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Use of Estimates</u></i>. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance-based compensation expense, among others. These estimates and assumptions are based on management&#x2019;s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.</p> </div>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58511000 shares
osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
1787000
us-gaap Contracts Revenue
ContractsRevenue
12837000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19442000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
15025000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
28626000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-205000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4152000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
558000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-564000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-75000
us-gaap Gross Profit
GrossProfit
64073000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19803000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13158000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3818000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-90000
us-gaap Income Taxes Paid
IncomeTaxesPaid
812000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1829000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1236000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
634000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-125000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1186000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3512000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
25180000
us-gaap Operating Expenses
OperatingExpenses
50881000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2784000
us-gaap Net Income Loss
NetIncomeLoss
12524000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
241000
us-gaap Operating Income Loss
OperatingIncomeLoss
13192000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2501000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
14413000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
367000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
22966000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3311000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3512000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
22966000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
894000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8547000
us-gaap Revenues
Revenues
92699000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
78286000
us-gaap Share Based Compensation
ShareBasedCompensation
4438000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22531000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56273000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55549000 shares
osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
203000
CY2015Q2 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
8600000
CY2015Q2 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
10400000
CY2015Q2 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
1800000
CY2015Q2 osur Contract Expiration Period
ContractExpirationPeriod
P3Y
CY2015Q3 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
7200000
CY2017Q3 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
1330000
CY2016Q3 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
9600000
CY2016Q3 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
16600000
CY2016Q3 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
7000000
CY2016Q3 osur Contract Expiration Period
ContractExpirationPeriod
P6Y
CY2016 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0
CY2016 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
217000
CY2016Q3 us-gaap Contracts Revenue
ContractsRevenue
6114000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5513000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
9576000
CY2016Q3 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
6242000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6144000
CY2016Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1414000
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2016Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
84000
CY2016Q3 us-gaap Gross Profit
GrossProfit
22675000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6907000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6642000
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
877000 shares
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
16531000
CY2016Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-729000
CY2016Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
6791000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
498000
CY2016Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
783000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3196000
CY2016Q3 us-gaap Revenues
Revenues
32251000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25460000
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6428000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56530000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55653000 shares
CY2016Q3 osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
203000
CY2017Q3 us-gaap Contracts Revenue
ContractsRevenue
0
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8088000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
17670000
CY2017Q3 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1698000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2017Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-638000
CY2017Q3 us-gaap Gross Profit
GrossProfit
24644000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6935000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7432000
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2082000 shares
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1669000
CY2017Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-245000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
17325000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
5763000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
7319000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2570000
CY2017Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
1157000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62172000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60090000 shares
CY2017Q3 osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
553000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
113000
CY2017Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1895000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3228000
CY2017Q3 us-gaap Revenues
Revenues
42314000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
41157000
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7162000

Files In Submission

Name View Source Status
0001193125-17-338742-index-headers.html Edgar Link pending
0001193125-17-338742-index.html Edgar Link pending
0001193125-17-338742.txt Edgar Link pending
0001193125-17-338742-xbrl.zip Edgar Link pending
d480771d10q.htm Edgar Link pending
d480771dex311.htm Edgar Link pending
d480771dex312.htm Edgar Link pending
d480771dex321.htm Edgar Link pending
d480771dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
osur-20170930.xml Edgar Link completed
osur-20170930.xsd Edgar Link pending
osur-20170930_cal.xml Edgar Link unprocessable
osur-20170930_def.xml Edgar Link unprocessable
osur-20170930_lab.xml Edgar Link unprocessable
osur-20170930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending